Erratum: Refining the benefit-risk framework for the assessment of medicines: Valuing and weighting benefit and risk parameters (Clinical Pharmacology and Therapeutics (2011) 89 (179-182) DOI: 10.1038/clpt.2010.290);Refining the benefit-risk framework for the assessment of medicines: Valuing and weighting benefit and risk parameters

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 2, 2011, Pages 179-182

  Walker, S ^a   Liberti, L ^a   McAuslane, N ^a  

^a CMR International Institute for Regulatory Science   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT;

CASE STUDY; CONCEPTUAL FRAMEWORK; DECISION MAKING; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; MEDICINE; PARAMETER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

EID: 78951480226     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.84     Document Type: Erratum

References (5)

1. Walker, S., McAuslane, N., Liberti, L. & Salek, S. Measuring benefit and balancing risk: strategies for the benefit-risk assessment of new medicines in a risk-adverse environment. Clin. Pharmacol. Ther. 85, 241-246 (2009).
2. Mussen, F., Salek, S. & Walker, S.R., Eds. Benefit-Risk Appraisal of New Medicines: A Systematic Approach to Decision Making (John Wiley Surrey, UK 2009).
3. Liberti, L., McAuslane, N. & Walker, S.R. Progress on the development of a benefit/risk framework for evaluating medicines. Reg. Focus 15, 32-37 (2010).
4. European Medicines Agency. Benefit-risk methodology project. Work Package 2 Report: Applicability of Current Tools and Processes for Regulatory Benefit-Risk Assessment (31 August 2010).
5. Walker, S., McAuslane, N., Liberti, L. & Connelly, P. Refining the benefit-risk framework for the assessment of medicines: valuing and weighting benefit and risk parameters. CMR International Institute for Regulatory Science Workshop report, June 2010.